Scientists of Saarland University have recently succeeded in developing the first CYP11B1 inhibitors showing good selectivity. As starting point the highly active CYP11B1 inhibitor Etomidate has been used. Via several modifications followed by further optimizations realized at this molecule, it was possible to increase the selectivity resulting in a very weak inhibition towards CYP11B2 and no inhibition of CYP17 and CYP19.
Weitere Informationen: PDF
Universität des Saarlandes Wissens- und Technologietransfer GmbH PatentVerwertungsAgentur der saarländischen Hochschulen
Tel.: +49 (0)681/302-71302
Ansprechpartner
Dipl.-Kfm. Axel Koch (MBA), Dr. Conny Clausen, Dr. Hauke Studier, Dr. Susanne Heiligenstein
